314 results about "Oral solutions" patented technology

The present invention provides a hydrangea oral liquid and a preparation method thereof, and relates to the field of biological fermentation technology. The preparation method of the hydrangea oral liquid of the present invention comprises: crushing the dried hydrangea fruiting bodies, mixing with glucose and water, ultrasonic treatment, obtaining a mixed material, inoculating a composite bacterial agent for fermentation, adding a composite enzyme for enzymolysis, filtering and concentrating, and obtaining the hydrangea oral liquid. The present invention combines hydrangea crushing with ultrasound, improves the dissolution of nutrients in hydrangea, and shortens the fermentation time; the composite bacterial agent fermentation can significantly increase the polysaccharide substances in the hydrangea oral liquid, and enhances the antioxidant effect; the composite bacterial agent fermentation of hydrangea and the composite enzyme enzymolysis can significantly improve the mushroom smell caused by the hydrangea itself. The experimental results show that the hydrangea oral liquid prepared by the method of the present invention can improve the mushroom smell caused by hydrangea, increase the polysaccharide content, and enhance the antioxidant performance.

The invention discloses a quality control method based on a levocarnitine oral solution preparation process, and relates to the technical field of quality detection. The quality control method based on the preparation process of the levocarnitine oral solution comprises the following steps: acquiring oral solution monitoring data; evaluating oral liquid quality; feeding back a result; and optimizing quality control parameters. According to the method, oral liquid quality evaluation is carried out through the obtained oral liquid monitoring data, the process quality feedback data is obtained, then the process parameter algorithm model is constructed according to the process quality feedback data, result feedback is carried out, and finally whether quality control parameter optimization is carried out or not is judged based on the process parameter algorithm model. The effect of improving the character stability of the prepared levocarnitine oral solution is achieved, and the problem that in the prior art, the quality of the prepared levocarnitine oral solution is difficult to control is solved.

The invention discloses a CAD detection method for phosphoric acid and phosphorous acid in an alendronate sodium oral solution, and belongs to the technical field of pharmaceutical analysis. The method comprises the following steps: preparing a reference stock solution and a test solution; then setting high performance liquid chromatography detection conditions; a Shodex VN-504D chromatographic column is adopted, a CAD detector is adopted as a detector, a mixed solution of a mobile phase A and a mobile phase B is adopted as a mobile phase, the mobile phase A is ammonium formate, the mobile phase B is an acetonitrile solution, and gradient elution is performed by adopting the mobile phase; and respectively measuring the reference stock solution and the test solution, injecting into a liquid chromatograph, and recording a chromatogram. A CAD detector is adopted, the detection sensitivity is obviously improved, the quantitative concentration can reach 0.24 mu g / mL, and the detection concentration can reach 0.10 mu g / mL. The method is high in specificity, high in sensitivity, good in durability, rapid, simple, effective and reliable.

The invention provides a detection method for related substances in loxoprofen sodium oral solution. The adopted ternary mobile phase system solves the interference of auxiliary materials in the low absorption band on the detection of known impurities, thereby avoiding the problem of missed detection and insufficient detection of impurities, effectively solving the interference of auxiliary material methylparaben on the detection of impurities when the related substances are determined, and the types and numbers of impurities to be monitored are large, the separation between various impurities, between impurities and main components, and between impurities and auxiliary materials is good, the related substances in the loxoprofen sodium oral solution can be quickly and accurately monitored, and the method has important significance for the quality evaluation of the loxoprofen sodium oral solution.

The invention belongs to the technical field of analysis and detection of medicine related components, and particularly relates to a method for determining related substances of a methotrexate oral solution, the related substances comprise methotrexate impurity B, impurity C, impurity E, impurity D, impurity H and impurity I. The determination method adopts a high performance liquid chromatography method. A mobile phase of the high performance liquid chromatography comprises a mobile phase A and a mobile phase B, the mobile phase A is a buffer salt solution, the mobile phase B is acetonitrile, and gradient elution is adopted. According to the method, a plurality of known impurities in the methotrexate oral solution can be measured at the same time by utilizing the high performance liquid chromatography, interference generated by a blank solvent and an auxiliary material solution is eliminated, and the method can be used for accurately and quantitatively detecting related substances in the preparation process and the storage process of the methotrexate oral solution and serves as an important component for medicine quality control. The clinical use risk is reduced. The method is good in specificity, good in separation degree, good in accuracy and high in practicability in actual quality control work.

The invention belongs to the technical field of health-care products, and provides nano donkey-hide gelatin oral liquid and a preparation method thereof. The preparation method comprises the following steps: S1, crushing colla corii asini, mixing the crushed colla corii asini with a surfactant solution, and performing ultrasonic treatment to obtain coated colla corii asini particles; s2, mixing jujubes, Chinese wolfberry fruits and haws, crushing to obtain a mixture, mixing the mixture, the coated donkey-hide gelatin particles and water, and extracting to obtain an extracting solution; s3, concentrating the extracting solution to obtain a concentrated solution; s4, mixing the concentrated solution, psicose and astaxanthin, and performing nanoscale homogenization treatment to obtain the nano donkey-hide gelatin oral liquid. A layer of protective film is formed on the surface of the donkey-hide gelatin fine powder through a surface modification technology, so that the agglomeration phenomenon of the donkey-hide gelatin in the extraction process is effectively prevented. The donkey-hide gelatin particles are further refined through high-pressure homogenization treatment, so that the donkey-hide gelatin particles reach the nanoscale, and the solubility and bioavailability of the donkey-hide gelatin are remarkably improved.

The invention discloses an ebastine oral solution preparation method, which comprises: 1, weighing 5-20 parts by mass of ebastine, 50-100 parts by mass of a thickening agent, 10-18 parts by mass of a bacteriostatic agent, 1800-2000 parts by mass of a thickening agent, 0.1-0.2 part by mass of a defoaming agent, 600-700 parts by mass of a sweetening agent, adjusting the pH value to 3.5-4.5 by using a pH value adjusting agent, and carrying out a proper amount of water; 2, adjusting the temperature to 35 DEG C, adding ebastine into the thickening agent, and stirring to completely disperse the ebastine; 3, adding part of purified water, an acidity regulator and a thickening agent, and stirring until the materials are completely dissolved; 4, adding the sweetening agent, the bacteriostatic agent and the defoaming agent, and stirring until the materials are completely dissolved; 5, cooling after complete dissolution, and adjusting the pH value to 4 by using an alkaline regulator; step 6, fixing the volume; by optimizing the preparation process, efficient dissolution of the ebastine oral solution is realized, the problems of clinical application pain points of tablets and low solubility of raw material medicines of the oral solution are solved, and a safer and more convenient treatment choice is provided for special crowds.

The invention belongs to the technical field of medicines, and provides a calcium zinc gluconate oral solution and a preparation method thereof. According to the invention, the sugar alcohol chelating agent is added into the calcium zinc gluconate oral solution, so that the effects of chelating and surface activity can be exerted at the same time, and the higher absorption and mobility of sugar alcohol can be utilized to drive calcium and zinc elements to be better absorbed. Preferably, sorbitol can form a sorbitol calcium ion chelate and a sorbitol zinc ion chelate with calcium ions in calcium gluconate and zinc ions in zinc gluconate, so that the stability and water solubility of the sorbitol calcium ion chelate and the sorbitol zinc ion chelate are improved, and precipitation of grape calcium carbonate and zinc gluconate is avoided; further, the solubility and the stability of the calcium gluconate and the zinc gluconate in the solution are improved. In addition, after the sorbitol is added, the low-temperature (2-8 DEG C) precipitation of the calcium gluconate is greatly improved. In addition, sorbitol has a fresh and sweet taste, so that the calcium zinc gluconate oral liquid has a good taste.

The invention relates to the technical field of medical preparations, in particular to a preparation method of an atomoxetine hydrochloride oral solution. The atomoxetine hydrochloride oral solution disclosed by the invention is prepared from the following raw materials in parts by weight: 5 to 15 parts of atomoxetine hydrochloride inclusion compound, 0.3 to 0.5 part of sodium benzoate, 16 to 17 parts of sorbitol, 165 to 170 parts of xylitol, 5 to 10 parts of sucralose, 1 to 2 parts of raspberry essence and 300 to 350 parts of deionized water. The atomoxetine hydrochloride oral solution disclosed by the invention has the advantages that in a taste experiment, the atomoxetine hydrochloride oral solution has obvious sweet taste and is well received by testers, the bitter taste of atomoxetine hydrochloride does not exist after the atomoxetine hydrochloride oral solution is eaten, and most importantly, after an acceleration experiment, the atomoxetine hydrochloride oral solution still has good taste and stability.

The invention provides a dexketoprofen trometamol oral solution and a preparation method thereof. According to the dexketoprofen trometamol oral solution, polyethylene glycol 400 and hydroxypropyl methylcellulose are used as stabilizing agents, methylparaben and propyl hydroxybenzoate are used as bacteriostatic agents, sucralose and ammonium glycyrrhizinate are used as sweetening agents, essence is used as a flavoring agent, and the pH value of the solution is controlled to be 6.2-6.8 through a pH value regulator. The increase of the impurity A, the impurity B, the impurity C, the impurity E and the total impurity is obviously reduced, so that the product stability is obviously improved.

Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.

The utility model relates to the technical field of oral solution filling, in particular to an oral solution filling device which is characterized in that an upper plate is mounted on the circumferential wall of a base through a connecting frame, a filling structure is mounted on the upper plate and comprises a box body, and a sealing structure for controlling filling is arranged on the circumferential wall of the box body; the sealing blocking plug is in contact with the through hole through the conical surface, a spring is installed between the sealing blocking plug and the box body, it can be guaranteed that the sealing blocking plug is in contact with the through hole through the spring, when the sealing blocking plug bears external pressure, the inner cavity of the box body is communicated with the outside through the through hole, and when the pressure is removed, the sealing blocking plug recovers to the state of sealing the box body again under the thrust of the spring; the sleeve is communicated with the inner cavity of the box body only through the ventilation pipe, the ventilation pipe is vertically arranged upwards, the end, away from the sleeve, of the ventilation pipe is close to the upper wall of the box body, when the sealing blocking plug is pushed to communicate the inner cavity of the box body with the outside, the ventilation position is close to the top face of the box body, and therefore the oral solution is prevented from flowing out of the through hole.

The invention relates to the technical field of pharmaceutical analysis, in particular to a detection method of a compound sodium picosulfate oral solution, which is used for detecting sodium picosulfate and related substances. The detection method comprises the following steps: carrying out liquid chromatography detection on the compound sodium picosulfate oral solution; the conditions of the liquid chromatography detection are as follows: (1) a chromatographic column is a reverse C18 chromatographic column or an efficiency equivalent column thereof; (2) taking a mixed solution of an ammonium acetate buffer salt solution and methanol as a mobile phase A and acetonitrile as a mobile phase B; wherein the pH value of the ammonium acetate buffer salt solution is 4.9 to 5.2; and (3) gradient elution is adopted. The quality detection method disclosed by the invention can be used for the preparation process of the compound sodium picosulfate oral solution and the quality control of the final product, is good in specificity, good in separation degree, high in sensitivity and good in reproducibility, and has important significance for evaluating the advantages and disadvantages of synthesis and preparation processes, controlling the quality of the final product and detecting a stable sample.

Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.

Disclosed herein is a ready-to-use, non-aqueous oral solution of losartan. Also disclosed herein is a method of preparing a ready-to-use, non-aqueous oral solution of losartan and its method of use.

The invention relates to a method for determining the content of sorbitol and glycerol as auxiliary materials in a fudosteine oral solution, which has the advantages of high sensitivity, strong specificity, good accuracy and simple and rapid operation, can reduce the difficulty of preparation development, reduce the workload of prescription development, shorten the research and development time and further improve the BE passing rate, and has practical significance.

The application belongs to the technical field of drug dissolution and dispersion, and particularly relates to a bunazosin water-based solution preparation and a preparation method. The bunazosin water-based solution preparation provided by the application comprises the following components: bunazosin, gamma-cyclodextrin, lecithin, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, aspartame and water. The above components are mixed to be homogeneous to prepare an oral solution which is uniform, clear and can be stored for a long time. The scheme of the application further enriches the dosage form of bunazosin, improves the convenience of taking bunazosin, and is expected to help improve the oral bioavailability and absorption efficiency of bunazosin. The scheme of the application also provides a reference direction for the mechanism research on the dissolution and dispersion behavior of the insoluble bunazosin macromolecule in a water medium.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an ambroxol hydrochloride-containing oral liquid and application thereof, and the ambroxol hydrochloride oral liquid is composed of ambroxol hydrochloride, ligustrazine, meglumine, dextran 40, xylitol, carboxymethylcellulose, L-tryptophan, stevioside and purified water. The ligustrazine and the ambroxol hydrochloride play a synergistic effect, and the meglumine and the dextran 40 are combined for use, so that the stability of the ambroxol hydrochloride is improved. Accelerated experiments show that the ambroxol hydrochloride is stable in property and suitable for further industrial mass production.

The present application provides a detection method and quality control method for related substances in dextromethorphan oral solution, which comprises the following steps: dissolving dextromethorphan oral solution in a solvent to obtain a test solution; and performing high performance liquid chromatography detection on the test solution; the mobile phase used in the high performance liquid chromatography detection comprises mobile phase A and mobile phase B, the mobile phase A comprises a phosphate solution, the mobile phase B comprises acetonitrile, and the concentration of the phosphate solution is 0.1 mM-10 mM. The detection method has good linear relationship between dextromethorphan and related substances, good accuracy and sensitivity, strong specificity, high stability, good separation degree and good reproducibility, and is suitable for wide application.

The invention relates to the technical field of medicines, in particular to a briracetam oral solution and a preparation method thereof. According to the present invention, by adjusting the formula and the preparation process of the oral solution of the briracetam, the stability of the briracetam is effectively improved, the antibacterial effect is effectively improved without adding the preservative, the taste of the oral solution is adjusted, and the medication compatibility of children patients is improved.

1. Name of the designed product: packing box (milk fruit sugar oral solution). 2. Use of the designed product: for product packing. 3. Design points of the designed product: combination of shape and pattern. 4. Picture or photo showing the design points: perspective view 1.

The utility model discloses atomoxetine hydrochloride oral solution filling equipment, which belongs to the field of oral solution filling, and comprises a support frame and a push plate, a conveying mechanism is arranged above the support frame, two limiting plates are symmetrically arranged on two sides of the top of the support frame, the two limiting plates are arranged on two sides of the conveying mechanism, and the push plate is arranged on the support frame. Empty bottles are evenly placed on the surface of the conveying mechanism, the empty bottles are placed between the two limiting plates, fixing frames are symmetrically arranged on the surfaces of the two sides of the supporting frame, the fixing frames are vertically arranged, a top plate is fixed to the tops of the four fixing frames, and the top plate is arranged above the conveying mechanism in a suspended mode. And air cylinders are symmetrically and vertically arranged on the two sides of the top of the top plate, push plates capable of getting close to or getting away from each other are arranged on the two sides above the conveying mechanism, and the push plates on the two sides can be moved to get close during filling, so that empty bottles are extruded through positioning V-shaped grooves in the surfaces, then the empty bottles are calibrated, the accuracy during filling is guaranteed, and liquid leakage is prevented.

The invention discloses a data security traceability system and method in an oral solution medicine production process, and belongs to the technical field of medicine data security traceability. The system comprises a data traceability module which constructs an information data traceability chain based on each group of factory oral solution drugs; the source data calling module is used for calling the information data traceability chain of the oral solution medicine with the query information and marking source data; the risk analysis module is used for determining risk data of the oral solution medicine on the basis of a plurality of pieces of source data and the number of the marked query information corresponding to each piece of source data; the medicine distribution area management module is used for determining the number of oral solution medicines with risk data in each area based on the transportation data of the medicine distribution area; and the safety early warning module is used for judging whether a disease spreading risk exists or not based on the sales data of the medicine distribution area. According to the invention, abnormal data in the drug production and circulation process can be accurately locked through the traceability system, and the transparency of drug information is improved.

The present invention relates to the field of pharmaceutical technology, and more particularly to a compound sodium picosulfate oral solution and a preparation method thereof. The oral solution comprises the following components: sodium picosulfate, anhydrous citric acid, magnesium oxide, a stabilizer, an antibacterial agent, and a pH adjuster, wherein the antibacterial agent comprises methylparaben and propylparaben in a mass ratio of 15:1-6:1. The present invention has the advantages of high stability and good antibacterial efficacy.

The present application relates to the field of pharmaceutical analysis, and particularly relates to a method for determining the content of cetirizine hydrochloride and preservatives in cetirizine hydrochloride oral solution. The method provided by the present application uses octadecyl bonded silica as the filler of the chromatographic column, uses a mixed solution with specific composition and proportion as the mobile phase, adopts isocratic elution, uses a content volumetric pipette to prepare the test sample solution, injects the test sample solution and the mixed control solution into the liquid chromatograph respectively to perform liquid chromatography, thereby obtaining the chromatogram of the test sample solution and the chromatogram of the mixed control solution respectively; and then according to the external standard method, the content of cetirizine hydrochloride, the content of the hydroxy methylbenzoate preservative and the content of the hydroxy propylbenzoate preservative in the cetirizine hydrochloride oral solution are calculated by the peak area. The method has strong specificity, high accuracy, good precision, linear relationship and stability, and is conducive to the evaluation of sample quality.

1. Name of the designed product: medicine packing box (vitamin D oral solution). 2. Use of the designed product: packing for vitamin D oral solution. 3. Design points of the designed product: in the pattern. 4. Picture or photo best indicating the design points: perspective view.

Liquid formulation including cevimeline hydrochloride and a combination of at least one sweetener and at least one flavoring agent to mask the bitter taste of cevimeline hydrochloride oral solutions. The liquid formulation may be administered to a patient to alleviate dry mouth symptoms associated with xerostomia and Sjogren's syndrome.

The invention discloses a method for determining the content of p-hydroxybenzoic acid in a procaterol hydrochloride oral solution. The method comprises the following steps: (1) preparing chromatographic conditions of a high performance liquid chromatography; (2) taking a procaterol hydrochloride oral solution to be detected as a test solution; (3) dissolving a p-hydroxybenzoic acid reference substance in a solvent, and quantitatively diluting to prepare a reference substance solution for later use, wherein about 0.22 mu g of p-hydroxybenzoic acid is contained in each 1ml of reference substance solution; (4) measuring the test solution and the reference solution, respectively injecting the test solution and the reference solution into a liquid chromatograph, recording chromatograms, and calculating the concentration by peak area according to an external standard method, the detection wavelength being 254-300nm; the column temperature of the chromatographic column is 35-45 DEG C; the flow rate is 0.9 to 1.1 ml per minute; the sample injection volume is 20-100 [mu] l. According to the method, the separation degree of a p-hydroxybenzoic acid peak and an adjacent peak is good, interference generated by blank auxiliary materials and solvents can be effectively eliminated, and the method can be used for quality control of a final product of the procaterol hydrochloride oral solution.

The utility model discloses a kind of oral liquid bottle caps with quantitative drop hole, comprising: inner plug, insert in oral liquid bottle mouth;And outer cover, cover on oral liquid bottle mouth, and cover inner plug in it;The inner plug includes plug body;Dripping channel is provided in the middle part of the plug body, and dripping port is provided at the top of the plug body, and liquid inlet is provided at the bottom of the plug body, dripping port and dripping channel intercommunicate, and dripping channel and liquid inlet intercommunicate;Extension body structure is provided at the side of the plug body, airflow passage I that passes through up and down is provided in the extension body structure, airflow passage II that passes through up and down is provided in plug body, and airflow passage I is communicated with airflow passage II.The utility model does not need external suction tube or dropper, with quantitative dripping function, solve most oral solution in the course of taking cannot control medicine liquid drop speed and drop weight, cannot realize the problem of accurate quantitative dosing.

The invention relates to the technical field of pharmaceutical analysis, in particular to a method for determining the content of a sodium picosulfate oral solution. According to the method, high performance liquid chromatography is adopted for detection, a chromatographic column with octadecylsilane chemically bonded silica as a filler is selected, a phosphate buffer solution (10.9 g of monopotassium phosphate is taken, 1000ml of water is added to dissolve the monopotassium phosphate, and the pH value is adjusted to 3.5 with phosphoric acid) is taken as a mobile phase A, methanol is taken as a mobile phase B, and gradient elution is carried out. By adopting the method, the content of the sodium picosulfate oral solution can be effectively detected, the method has the advantages of strong specificity, good reproducibility, simplicity and convenience in operation and the like, and the quality of the sodium picosulfate oral solution can be effectively guaranteed.